Targeted Therapies for Multiple Myeloma.

J Pers Med · 2021 · PMC8145732 · PMID 33922567

Europe PMC DOI

hedged sentences

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendp = 0.09so close (0.05 < p ≤ 0.1)

The addition of elotuzumab to Vd in a phase II clinical trial showed a trend towards increased OS and PFS (median, 9.7 vs. 6.9 months, p = 0.09) but did not reach statistical significance [ 107 ].

also in 53,322 other papers

did not reach statistical significanceno p-value reported

6.9 months, p = 0.09) but did not reach statistical significance [ 107 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.